Registration Agreement and Approval of Nasodine in Indonesia
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Firebrick Pharma Limited has announced the approval of Nasodine Nasal Spray for importation and distribution in Indonesia, marking its first regulatory approval for the product. The approval allows Firebrick to access the Indonesian market, which is significant due to its large population and status as the largest market in Southeast Asia. The company plans to manufacture the product with local language packaging and secure a marketing partner before commencing sales.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- December 2025 Quarterly Activity Report & Appendix 4C
- Nasodine Throat Spray Product Launch in Singapore
- Firebrick announces new product Nasodine Throat Spray
- September 2025 Quarterly Activity Report & Appendix 4C
Later from Firebrick Pharma
- Trading Halt
- Firebrick Secures $1.5 million via Placement
- March 2026 Quarterly Activity Report & Appendix 4C
- Investor Update
- Proposed issue of securities - FRE
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma